HR 6227 · 118th Congress · Health

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

Introduced 2023-11-03· Sponsored by Rep. Schweikert, David [R-AZ-1]· House

Bill Progress

✓
Introduced
2
Committee
3
House Vote
4
Senate
5
Enacted
Latest: Referred to the Subcommittee on Health.(2023-11-10)

Plain Language Summary

[AI summary unavailable — showing source text] Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023 This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.…

Summarized by Claude AI · Non-partisan · For informational purposes only

Cosponsors (20)

9 Democrats11 Republicans
Rep. McCarthy, Kevin [R-CA-20]CA
Rep. Burgess, Michael C. [R-TX-26]TX
Rep. Self, Keith [R-TX-3]TX
Rep. Ciscomani, Juan [R-AZ-6]AZ
Rep. Armstrong, Kelly [R-ND-At Large]ND
Rep. Gallego, Ruben [D-AZ-3]AZ
Rep. Caraveo, Yadira [D-CO-8]CO
Rep. Costa, Jim [D-CA-21]CA
Rep. Grijalva, Raúl M. [D-AZ-7]AZ
Rep. Steel, Michelle [R-CA-45]CA
Rep. Levin, Mike [D-CA-49]CA
Rep. De La Cruz, Monica [R-TX-15]TX
Rep. Valadao, David G. [R-CA-22]CA
Rep. Lesko, Debbie [R-AZ-8]AZ
Rep. Swalwell, Eric [D-CA-14]CA
Rep. LaMalfa, Doug [R-CA-1]CA
Rep. Pettersen, Brittany [D-CO-7]CO
Rep. Stansbury, Melanie Ann [D-NM-1]NM
Rep. Obernolte, Jay [R-CA-23]CA
Rep. Peters, Scott H. [D-CA-50]CA